Profile data is unavailable for this security.
About the company
Respiratorius AB (publ) is a Sweden-based biotechnology and pharmaceutical company. It develops candidate drugs for treatment of cancer, Chronic Obstructive Pulmonary Disease (COPD) and asthma. The project portfolio also includes development of a biomarker for cardiovascular positron-emission tomography (PET)-imaging. The oncology drug project VAL-001 aims for first-line treatment of Diffuse Large B-Cell Lymphoma (DLBCL). In the COPD and asthma projects, the Company develops two classes of drug substances, such as RESP-1000 and RESP-2000 series for bronchodilating effect on small airways. The Company’s primary markets are the United States and South Africa.
- Revenue in SEK (TTM)1.35m
- Net income in SEK-7.30m
- Incorporated1998
- Employees--
- LocationRespiratorius AB (publ)Medicon Village, Scheeletorget 1LUND 223 81SwedenSWE
- Phone+46 709224140
- Websitehttps://www.respiratorius.com/
More ▼